Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
Journal for Immunotherapy of Cancer
|
January 22, 2026
RIG-I agonists promote antigen-spreading and facilitate durable CAR-T responses in pancreatic ductal adenocarcinoma
Anne Marie Senz, Bruno L Cadilha, Julia Teppert, et al.
Journal of the National Cancer Institute
|
November 27, 2014
Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer
Sebastian Kobold, Julius Steffen, Michael Chaloupka, et al.
International Journal of Molecular Sciences
|
November 18, 2020
IL-18 but Not IL-1 Signaling Is Pivotal for the Initiation of Liver Injury in Murine Non-Alcoholic Fatty Liver Disease
Simon Hohenester, Veronika Kanitz, Tobias Schiergens, et al.
Leukemia
|
November 20, 2019
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade
Michael Ruzicka, Lars M Koenig, Simone Formisano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 2004
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors
Eugene Maraskovsky, Sigrid Sjölander, Debbie P Drane, et al.
Frontiers in Immunology
|
May 17, 2021
Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis Virus in a Replication Dependent Manner
Andreas Linder, Viktoria Bothe, Nicolas Linder, et al.
Nature
|
April 30, 2010
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Peter Duewell, Hajime Kono, Katey J Rayner, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2017
Cancer cells induce interleukin-22 production from memory CD4<sup>+</sup> T cells via interleukin-1 to promote tumor growth
Cornelia Voigt, Peter May, Adrian Gottschlich, et al.
Science Immunology
|
July 17, 2021
OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis
Daniel F R Boehmer, Simone Formisano, Carina C de Oliveira Mann, et al.
Molecular Cancer Therapeutics
|
June 25, 2026
RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma model
Charlotte Marx, Julia Teppert, Laura Marisch, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
Journal for Immunotherapy of Cancer
|
January 22, 2026
RIG-I agonists promote antigen-spreading and facilitate durable CAR-T responses in pancreatic ductal adenocarcinoma
Anne Marie Senz, Bruno L Cadilha, Julia Teppert, et al.
Journal of the National Cancer Institute
|
November 27, 2014
Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer
Sebastian Kobold, Julius Steffen, Michael Chaloupka, et al.
International Journal of Molecular Sciences
|
November 18, 2020
IL-18 but Not IL-1 Signaling Is Pivotal for the Initiation of Liver Injury in Murine Non-Alcoholic Fatty Liver Disease
Simon Hohenester, Veronika Kanitz, Tobias Schiergens, et al.
Leukemia
|
November 20, 2019
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade
Michael Ruzicka, Lars M Koenig, Simone Formisano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 2004
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors
Eugene Maraskovsky, Sigrid Sjölander, Debbie P Drane, et al.
Frontiers in Immunology
|
May 17, 2021
Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis Virus in a Replication Dependent Manner
Andreas Linder, Viktoria Bothe, Nicolas Linder, et al.
Nature
|
April 30, 2010
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Peter Duewell, Hajime Kono, Katey J Rayner, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2017
Cancer cells induce interleukin-22 production from memory CD4<sup>+</sup> T cells via interleukin-1 to promote tumor growth
Cornelia Voigt, Peter May, Adrian Gottschlich, et al.
Science Immunology
|
July 17, 2021
OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis
Daniel F R Boehmer, Simone Formisano, Carina C de Oliveira Mann, et al.
Molecular Cancer Therapeutics
|
June 25, 2026
RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma model
Charlotte Marx, Julia Teppert, Laura Marisch, et al.
Page
of 7